Knowthestock.com
VTRS - Viatris Inc
SNP 500

Sell

Weak GrowthStock Price Very High
WeakStrong
WeakStrong

19%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -5.26%
Operating Income Growth is -52.55%
Net Income Growth is -97.37%
Earnings Per Share (EPS) Growth is -96.82%
Net Margin is 0.35%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.67
Debt Ratio is 0.57
Current Debt to Net Income Ratio is 35.53
Total Debt to Total Assets Ratio is 0.37
Cash Flow is MODERATE
Cash from Operations Growth is -5.18%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Viatris Inc (VTRS) - www.viatris.com
Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. It provides access to medicines, advance sustainable operations, develop innovative solutions and leverage its collective expertise to connect more people to more products and services through its one-of-a-kind Global Healthcare GatewayTM. Formed in November 2020through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghaiand Hyderabad, India.
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Michael Goettler
Employees - 2,020
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.